UCLA SPORE in Prostate Cancer
UCLA SPORE 在前列腺癌中的应用
基本信息
- 批准号:8548477
- 负责人:
- 金额:$ 215.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-09-15 至 2018-08-31
- 项目状态:已结题
- 来源:
- 关键词:AnatomyAndrogen ReceptorAreaAttentionBioinformaticsBiological MarkersBiometryCancer PatientCastrationCell NucleusChemistryClinicClinicalDevelopmentDiagnosisDiet ModificationDisciplineDiseaseEngineeringEnvironmentFDA approvedFacultyFat-Restricted DietFosteringFundingGoalsHumanImageInstitutesInstitutionInterdisciplinary StudyLaboratory ResearchMalignant neoplasm of pancreasMalignant neoplasm of prostateMeasurableMolecularMorbidity - disease rateNanotechnologyNational Cancer InstituteNeoplasm Circulating CellsNeoplasm MetastasisOmega-3 Fatty AcidsOutcomePTEN genePathologyPathway interactionsPrimary PreventionProstateRadiology SpecialtyResearchResearch InfrastructureResearch PersonnelResearch SupportResistanceScientistSecondary PreventionSeminalServicesSignal PathwaySignal TransductionSisterSolutionsSpecimenStagingTalentsTechnologyTranslational ResearchTranslationsantibody engineeringanticancer researchbasecancer cellcancer stem cellcareer developmentclinical applicationclinical practicedata managementdesigndietary supplementshuman capitalimprovedinnovationmenmortalitynanosystemsnew technologynoveloutcome forecastpre-clinicalpreventprogramsprostate stem cell antigenstem cell biologytumor microenvironment
项目摘要
The UCLA Prostate Cancer SPORE is a multidisciplinary and translational research program focused on the development of new and innovative approaches for improving the diagnosis, prognosis, and treatment of prostate cancer patients. Initially built around a small nucleus of basic and clinical scientists, the program has expanded around campus to bring diverse talents from disciplines as varied as Chemistry, Nanotechnology, Stem Cell Biology, Pathology and Radiology to focus on the prostate cancer problem. This campus-wide (including UCLA affiliated-institutions) enterprise has led to significant discoveries with potential major impact on men with prostate cancer. The overall goal of this competitive renewal application is to continue to apply the diversity of talent on the UCLA
campus and its sister institutions to the critical and evolving translational challenges in the fied of prostate cancer. To achieve the long-term objectives and goals of our program, the Specific Aims of the UCLA SPORE in Prostate Cancer are:
1. Perform high-impact translational research focused on some of the major challenges in the field of prostate cancer by:
2. Provide organizational infrastructure and novel technologies designed specifically to support the translational research objectives of the SPORE:
3. Develop new prostate cancer researchers and research areas to advance translational research in prostate cancer
加州大学洛杉矶分校前列腺癌孢子是一个多学科和转化性研究计划,专注于开发新的和创新的方法来改善前列腺癌患者的诊断、预后和治疗。该项目最初是围绕基础和临床科学家的小圈子建立的,后来在校园内扩大,吸引了来自化学、纳米技术、干细胞生物学、病理学和放射学等不同学科的不同人才,专注于前列腺癌问题。这一校园范围(包括加州大学洛杉矶分校附属机构)的企业带来了重大发现,对患有前列腺癌的男性具有潜在的重大影响。此次竞争性续签申请的总体目标是继续将多样化的人才应用于加州大学洛杉矶分校
校园及其姊妹机构应对前列腺癌领域的关键和不断变化的翻译挑战。为了实现我们项目的长期目标和目标,加州大学洛杉矶分校前列腺癌分生孢子的具体目标是:
1.通过以下方式对前列腺癌领域的一些主要挑战进行高影响力的转化性研究:
2.提供专门为支持孢子翻译研究目标而设计的组织基础设施和新技术:
3.开发新的前列腺癌研究人员和研究领域,以推进前列腺癌的翻译研究
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT E REITER其他文献
ROBERT E REITER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT E REITER', 18)}}的其他基金
Multifunctional immunoPET tracers for pancreatic and prostate cancer
用于胰腺癌和前列腺癌的多功能免疫PET示踪剂
- 批准号:
9197062 - 财政年份:2013
- 资助金额:
$ 215.05万 - 项目类别:
Multifunctional immunoPET tracers for pancreatic and prostate cancer
用于胰腺癌和前列腺癌的多功能免疫PET示踪剂
- 批准号:
8641677 - 财政年份:2013
- 资助金额:
$ 215.05万 - 项目类别:
Multifunctional immunoPET tracers for pancreatic and prostate cancer
用于胰腺癌和前列腺癌的多功能免疫PET示踪剂
- 批准号:
9769635 - 财政年份:2013
- 资助金额:
$ 215.05万 - 项目类别:
Multifunctional immunoPET tracers for pancreatic and prostate cancer
用于胰腺癌和前列腺癌的多功能免疫PET示踪剂
- 批准号:
8532740 - 财政年份:2013
- 资助金额:
$ 215.05万 - 项目类别:
Imaging Prostate Cancer with Engineered PSCA Antibodies
使用工程化 PSCA 抗体对前列腺癌进行成像
- 批准号:
7315062 - 财政年份:2007
- 资助金额:
$ 215.05万 - 项目类别:
Imaging Prostate Cancer with Engineered PSCA Antibodies
使用工程化 PSCA 抗体对前列腺癌进行成像
- 批准号:
8094354 - 财政年份:2002
- 资助金额:
$ 215.05万 - 项目类别:
相似海外基金
Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
- 批准号:
DP230103210 - 财政年份:2023
- 资助金额:
$ 215.05万 - 项目类别:
Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
- 批准号:
10584689 - 财政年份:2023
- 资助金额:
$ 215.05万 - 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
- 批准号:
10650956 - 财政年份:2023
- 资助金额:
$ 215.05万 - 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
- 批准号:
10488954 - 财政年份:2023
- 资助金额:
$ 215.05万 - 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
- 批准号:
10651105 - 财政年份:2023
- 资助金额:
$ 215.05万 - 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
- 批准号:
10603636 - 财政年份:2023
- 资助金额:
$ 215.05万 - 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
- 批准号:
10544062 - 财政年份:2022
- 资助金额:
$ 215.05万 - 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
- 批准号:
10534943 - 财政年份:2022
- 资助金额:
$ 215.05万 - 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
- 批准号:
10677989 - 财政年份:2022
- 资助金额:
$ 215.05万 - 项目类别: